General Information of Drug (ID: DMVJWBS)

Drug Name
JSI-1187 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMVJWBS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [3]
HH2710 DM0C5MV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
ASTX029 DMVZXIA Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
VAN-10-4-eluting stent DM3ZW6A Artery stenosis BD52 Phase 1 [6]
GDC-0994 DMFC2OY Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
ASN007 DMYHEUA Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
COR-D DMLXMCB T-cell leukaemia 2A90 Preclinical [9]
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine DMDNG8F Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [3]
HH2710 DM0C5MV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
ASTX029 DMVZXIA Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
VAN-10-4-eluting stent DM3ZW6A Artery stenosis BD52 Phase 1 [6]
GDC-0994 DMFC2OY Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
LY3214996 DMFDAY7 Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [11]
COR-D DMLXMCB T-cell leukaemia 2A90 Preclinical [9]
SB220025 DMSBUET Arthritis FA20 Terminated [12]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular signal-regulated kinase 1 (ERK1) TT1MG9E MK03_HUMAN Inhibitor [2]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04418167) JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug name JSI1187).
3 DOI: 10.1158/1538-7445.AM2015-4693
4 Clinical pipeline report, company report or official report of HaiHe Biopharma.
5 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
7 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
10 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
11 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
12 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
13 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.